Bioceltix
Veterinary stem-cell therapy · Osteoarthritis (dogs, horses)
Overview
Allogeneic mesenchymal stem-cell therapeutics for companion animals; pursuing EMA centralized approval — would be a first-of-kind veterinary biologic out of Poland.
What they do
Bioceltix is a Wrocław-based, Warsaw Stock Exchange-listed veterinary biotech developing allogeneic mesenchymal stem-cell therapeutics for companion animals, principally dogs and horses. Using off-the-shelf (donor-derived) cell products manufactured to pharmaceutical-grade standards, it aims to bring regulated biologic medicines, rather than unregulated cell treatments, to veterinary medicine.
Lead program & status
Its most advanced candidate is BCX-CM-J, an allogeneic stem-cell therapy for osteoarthritis in dogs. Bioceltix is pursuing a centralized registration procedure with the European Medicines Agency (EMA); if approved, it is expected to be among the world's first veterinary medicinal products containing allogeneic canine stem cells. The company is also advancing BCX-CM-AD for canine atopic dermatitis, reporting successful final clinical results in 2025 and preparing an EMA submission, plus equine programs (BCX-EQ). To support commercialization, Bioceltix raised about PLN 52 million in a 2025 public offering and, reportedly in early 2026, secured environmental approval for a large-scale manufacturing facility in Wrocław.
Why it matters
A centrally approved allogeneic veterinary biologic out of Poland would be a genuine first-of-kind, opening a scalable, off-the-shelf product category in the fast-growing companion-animal health market.
FAQ
- What is BCX-CM-J?
- BCX-CM-J is Bioceltix's lead candidate, an allogeneic mesenchymal stem-cell therapy for osteoarthritis in dogs, undergoing a centralized EMA registration procedure.
- Why is Bioceltix considered first-of-kind?
- If approved, its lead product would be among the world's first veterinary medicinal products containing allogeneic (donor-derived) canine stem cells, manufactured to pharmaceutical standards.
- What other programs does Bioceltix have?
- Beyond canine osteoarthritis, it is developing BCX-CM-AD for canine atopic dermatitis, which reported positive final clinical results in 2025, plus equine (BCX-EQ) programs.
Technology
Bioceltix works in CAR-T Cell Therapy — Re-engineering a patient's own T-cells into living cancer hunters.
Read the CAR-T Cell Therapy brief →Related companies
Company website / source ↗ Open the interactive map →
Get ahead of the next biotech boom.
New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.